icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-nave non-cirrhotic patients with chronic HCV genotype 3 infection
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
C. HEZODE 1, V. LEROY 2, I. ROSA 3, F. ROUDOT-THORAVAL 1 , JM. PAWLOTSKY 4 , V. de LEDINGHEN 5 , and JP. BRONOWICKI 6
1 Hepatology, CHU Henri Mondor, Creteil, France; 2 Hepatology, CHU Michallon, Grenoble, France; 3 Hepatology, Hopital Intercommunal, Creteil, France 4 Virology, CHU Henri Mondor, Creteil, France; 5 Hepatology, CHU Haut Leveque, Bordeaux, France; 6 Hepatology, CHU de Brabois, Nancy, France

0501171

0501172

0501173